Member Info for inanaco

the �6 was linked to trial results, ...so lets not make up stories Tosh ... the reason why i don't have to explain, again is simple ... the sheer scale of the evidence is all positive from here on .... and your posts carry no reasoning ... just loud and persistent ... which is what Noise is ... which is why i do wander into .... areas where people have different views, strategies or reasoning. because i can separate Noise ..... highlight poor posts, and waffle .

the fact that he replied "who is tosh" would indicate that he is Tosh .......... only somebody seriously thick would do that. Officer ....

i mention interferon gamma and how if we see that cytokine its the evidence of our vaccines ,, wild from your link ... That recognition is leading many labs�including labs at Novartis�to look at ways to activate the immune system in patients with cold tumors, by generating what is called a type 1 interferon response, before giving the patients a checkpoint inhibitor. Learn about a collaboration that is advancing this research.

I think Tosh has eaten his foot again ... hope he has cleared up that fungal infection ...

Toshwing posts my point being, that �1.25 is a far more realistic , and maybe achievable , valuation over the next 6 months, then declares it was somebody else forecast that he agreed with ????? but now he does not ... OH dear ... don't tangle yourself up . mate

your post to steve dated Feb 26th .... or can't you remember what you post,

Its more to do with trying to generate threads of significance, sometime to motivate folks to post and research the science its been more productive to turn them negative than positive .... its only you have not actually understood why i do it Konar ... I agree i think outside the box, so i will always be controversial .. But considering i did spot the key to moditope .... "inducing stress in cancer" gives you some idea that i can actually THINK so i Don't do it to win friends, which IMHO would indicate EGO ... i do it to test Scancell and that all important word "risk analysis" as far as i am concerned its a financial BB .. not a mouth peace for Football fans, gamblers and general idiots and exactly where are the Negative Posters now .... GONE I Kinda won the argument ...

thing is, i can reason why the SP will get to �6.... can you reason why it will get to �1.25 ? the posts that i have done today ... can you argue against them, because if you cannot, you cannot dismiss �6 .. this is always the problem with "Thick" posters they claim numbers but cannot reason numbers . its a big difference so to combat posters like me they have to resort to Drama Queen posts, and we have seen that recently as well .. so our latest recruit to the Drama Queen Class is ... Hotwings .. welcome

maybe we should remind you of your own Forecast .... this is your post Hotwings ... �1.25 SCLPsteve26 Feb '18 agree with you �1.25 would be fantastic right now , but the modi data is still someway off, as is the scib II data. my point being, that �1.25 is a far more realistic , and maybe achievable , valuation over the next 6 months, rather than the �6 being touted ( for the umpteenth time over the last few years ) by a certain poster. even �1.25 is only a credible target, if / when, the funding issue is resolved... certainly NOT �6. otherwise its 10p - 25p max, for the foreseeable future. imho

claims are easy .. just fake news you can have an opinion .. but you cannot reason it exactly as you have just posted.

its an off the shelf approved product so anybody can run a trial with it as its current standard of care

yes its in RNS

Just so much going on .... Crumbs . Like i always said Scancell is number 1 yet to be proven wrong. Scancell will be the next Arm Holdings Yet to be proven wrong question is when will the SP catch up with Inanaco /crumbs/wildforce etc LOL MCap predictions are based around time frames, and market conditions which change ......... The fundamentals are not predictions ..

is ....... turning cold cancers hot its that simple ... TH1 slew It does not matter what i look at ... i can show the science works .... CONCLUSION: These data suggest that beta2-agonists in combination with low doses of steroids can suppress T-cell proliferation and TH1 cytokine production from healthy individuals, but suppression of T cells with a combination of FP and salmeterol in asthmatic patients requires inhibition of phosphodiesterases. so in this instance suppression of cytokine induced by TH1 t cells ..... Scancell wants the opposite .... third party data ... """" Risk analysis"""" so this article shows that Inducing TH1 will add to T-cell proliferation and cytokine production ... Inflaming the tumour https://www.ncbi.nlm.nih.gov/pubmed/15241363 which is why i keeo saying I cannot find a negative , nothing published would put into question what the science of scancell is all about

Is bigger that most Big Pharma Oncology pipeline ... when will folks actually understand that .......... Moditope is a Land Grab PD1 is only the Isles of Man in comparison, yet its worth Billions ...

I have tried to get folks to look at Portfolio and do a risk analysis of what they are holding unfortunately i only had dumb replies Modi1 is 4 targets ... (renal) maybe not going into trial at this stage but as funds allow it will. but has any one mentioned Modi2 potential .. ? Modi-2 targets multiple solid tumours (including oesophageal, gastric, colorectal, breast (non-TNBC), cervical, prostate, liver, renal, endometrial, bladder and thyroid tumours) and pre-clinical development of selected epitopes is planned during 2018. The Company expects to characterise its Modi-2 development candidate and begin GMP manufacturing in H2 2019. Both Modi-1 and Modi-2 will target tumours that are generally unresponsive to checkpoint inhibitor therapy. it can target 10 ........... (renal) doubles up ... again so few are reading the entire RNS at the cash raise so your seeing 13 cancers from two products ...

well you can dumb down to Loz,and Tosh's level .. but they still don't get it ....LOL

we have discussed recently about the commercial potential and the numbers relating to efficacy .... well take PD1 in lung cancer .... 20% receive benefit and the cost ? is 5 times the value of 1 treatment to get efficacy $150,000 x 5 = 1 patient receiving benefit Now look at Modi1 Continued progress has been made with the Moditope� platform, and the Company has identified and validated multiple targets, including enolase, which, together with vimentin, will form the basis for Modi-1, Scancell's first product derived from the Moditope� platform. Pre-clinical data suggests that Modi-1 should be effective in up to 90% of patients with TNBC, up to 95% of patients with ovarian cancer and up to 100% of patients with sarcoma. I can say with confidence that over the coming years that those numbers can be achieved because we have two shots on goal .... Good immune systems should respond to the Modi1 vaccine Poor immune systems ... will get a fresh batch of T cells programmed to search out autphagy via TCR therapy

Just wish folks would read the recent RNS on the cash raise ... two bits are fundamental as to why we continue to increase our holdings ..... 1/ Experimental data suggests that the high avidity T cells induced by ImmunoBody� vaccines increase expression of PDL-1 on the tumour cell surface, thereby making the tumours more sensitive to checkpoint inhibitor drugs. (this is exactly what i am referring to when i look at the risk analysis) third party Data confirms Increase PDl-1 expression when interaction with the bodies own T cells secrete cytokines that promote PDl-1 expression For those tumors that are cold ie little activity PD1 just has little benefit .... So hit them with SCIB1 .. bingo you have inflammation .. (cytokines) induced PDl-1 ... keytruda now does its job, and SCIB1 destroys the cancer as the keytruda blocks the cancer's suppression mechanism . 2/ The Company is continuing discussions on potential commercial partnership discussions for the Moditope� platform alongside its clinical development plans, with multiple partnering discussions in progress. whats interesting they have put on the back burner a deal on immunobody because of the value increase if synergy is established with Keytruda. Clearly both SCIB1 and SCIB2 are moving forward so its not the case that value is being left on the shelf. I still think Roche is very much in the Window to get involved commercially before the Grand Challenge Decision "the Value of that link" just wish i knew what it was.

I think the hardest bit to get across is the Scale of what Scancells IP can address ... and the Market potential is so enormous the risk reward ratio is off the charts with the current mcap ...